United Therapeutics (NASDAQ:UTHR) was downgraded by investment analysts at Credit Suisse Group from a “neutral” rating to an “underperform” rating in a research note issued on Wednesday.
A number of other research analysts have also issued reports on the stock. BidaskClub upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, July 11th. Barclays dropped their price target on shares of United Therapeutics from $105.00 to $95.00 and set an “underweight” rating on the stock in a research note on Thursday, May 3rd. Zacks Investment Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating and set a $127.00 price target on the stock in a research note on Saturday, July 7th. Wedbush boosted their price target on shares of United Therapeutics from $234.00 to $253.00 and gave the stock an “outperform” rating in a research note on Thursday, August 2nd. Finally, Cowen reiterated a “hold” rating and set a $110.00 price target on shares of United Therapeutics in a research note on Thursday, August 2nd. Two analysts have rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $138.86.
NASDAQ UTHR traded up $2.42 during trading on Wednesday, reaching $127.24. The company’s stock had a trading volume of 36,778 shares, compared to its average volume of 340,360. United Therapeutics has a twelve month low of $100.57 and a twelve month high of $152.55. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.35 and a current ratio of 4.64. The firm has a market cap of $5.54 billion, a PE ratio of 11.55, a P/E/G ratio of 32.49 and a beta of 1.28.
United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported $3.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $1.41. United Therapeutics had a net margin of 40.87% and a return on equity of 34.42%. The business had revenue of $444.50 million for the quarter, compared to analyst estimates of $368.63 million. During the same period in the previous year, the business posted $4.37 earnings per share. The business’s revenue was up .0% compared to the same quarter last year. research analysts predict that United Therapeutics will post 14.4 earnings per share for the current year.
In other United Therapeutics news, Director Judy D. Olian sold 600 shares of the company’s stock in a transaction dated Tuesday, June 12th. The shares were sold at an average price of $112.38, for a total transaction of $67,428.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Raymond Dwek sold 3,240 shares of the company’s stock in a transaction dated Friday, June 29th. The stock was sold at an average price of $113.07, for a total transaction of $366,346.80. The disclosure for this sale can be found here. Corporate insiders own 8.20% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Acadian Asset Management LLC purchased a new stake in shares of United Therapeutics in the second quarter valued at about $129,555,000. First Trust Advisors LP lifted its holdings in shares of United Therapeutics by 36.3% in the second quarter. First Trust Advisors LP now owns 684,956 shares of the biotechnology company’s stock valued at $77,503,000 after purchasing an additional 182,409 shares in the last quarter. LSV Asset Management lifted its holdings in shares of United Therapeutics by 53.3% in the first quarter. LSV Asset Management now owns 420,340 shares of the biotechnology company’s stock valued at $47,229,000 after purchasing an additional 146,194 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of United Therapeutics by 3.0% in the first quarter. BlackRock Inc. now owns 4,912,985 shares of the biotechnology company’s stock valued at $552,023,000 after purchasing an additional 141,416 shares in the last quarter. Finally, Mackay Shields LLC purchased a new stake in shares of United Therapeutics in the first quarter valued at about $14,199,000. Institutional investors own 98.50% of the company’s stock.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Further Reading: Growth Stocks, What They Are, What They Are Not
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.